Theriva Biologics, Inc. (TOVX) stock
TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.14+0.00 (0.00%)
Close on Nov 17, 2026Market cap $6.42MP/E –Yield –
Theriva Biologics r&d expenses
Research and development expenses are spending on new products and technology.
Theriva Biologics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.31M, down 49.7% year over year. For fiscal 2025 it was $8.60M, down 28.5% from the year before. Over ten years it grew -12.6% a year on average. The highest annual figure on record is $32.91M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.60M | -28.5% |
| FY2024 | Dec 31, 2024 | $12.03M | -15.9% |
| FY2023 | Dec 31, 2023 | $14.31M | +22.1% |
| FY2022 | Dec 31, 2022 | $11.72M | +50.3% |
| FY2021 | Dec 31, 2021 | $7.80M | +52.0% |
| FY2020 | Dec 31, 2020 | $5.13M | -53.7% |
| FY2019 | Dec 31, 2019 | $11.08M | -6.4% |
| FY2018 | Dec 31, 2018 | $11.84M | -36.9% |
| FY2017 | Dec 31, 2017 | $18.78M | -35.5% |
| FY2016 | Dec 31, 2016 | $29.11M | -11.5% |
| FY2015 | Dec 31, 2015 | $32.91M | +127.1% |
| FY2014 | Dec 31, 2014 | $14.49M | +122.7% |
| FY2013 | Dec 31, 2013 | $6.51M | -47.0% |
| FY2012 | Dec 31, 2012 | $12.29M | +267.9% |
| FY2011 | Dec 31, 2011 | $3.34M | +111.4% |
| FY2010 | Dec 31, 2010 | $1.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.27M | -35.1% |
| Q1 FY2026 | Mar 31, 2026 | $355.00K | -88.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.13M | -60.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.55M | -6.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.95M | -33.9% |
| Q1 FY2025 | Mar 31, 2025 | $2.97M | -14.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.89M | -31.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.73M | -31.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.95M | -5.7% |
| Q1 FY2024 | Mar 31, 2024 | $3.46M | +16.2% |
| Q4 FY2023 | Dec 31, 2023 | $4.20M | +36.6% |
| Q3 FY2023 | Sep 30, 2023 | $4.01M | +55.9% |
| Q2 FY2023 | Jun 30, 2023 | $3.13M | -10.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.98M | +14.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.07M | +10.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.57M | +30.3% |
| Q2 FY2022 | Jun 30, 2022 | $3.49M | +80.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.60M | +132.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.78M | +183.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.97M | +115.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.93M | +20.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.12M | -31.6% |
| Q4 FY2020 | Dec 31, 2020 | $979.00K | -49.2% |
| Q3 FY2020 | Sep 30, 2020 | $914.00K | -77.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.60M | -38.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.64M | -32.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.93M | -6.3% |
| Q3 FY2019 | Sep 30, 2019 | $4.14M | +45.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.59M | -27.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.42M | -28.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.06M | -45.3% |
| Q3 FY2018 | Sep 30, 2018 | $2.85M | -31.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.57M | -26.1% |
| Q1 FY2018 | Mar 31, 2018 | $3.37M | -44.4% |
| Q4 FY2017 | Dec 31, 2017 | $3.76M | -44.2% |
| Q3 FY2017 | Sep 30, 2017 | $4.14M | -41.4% |
| Q2 FY2017 | Jun 30, 2017 | $4.83M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.73M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.06M | – |
See a number that looks wrong?